Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology
Prevalence of Chronic inflammatory demyelinating polyneuropathy
7 evidence topics · 7 sources
United States: claims-based prevalence and estimated number of persons, 2023
“The adjusted rate was 23.3 (95% CI 23.1–23.5) per 100,000 persons, which corresponds to an estimated 77,058 individuals living with CIDP in the USA in 2023.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“corresponding to a raw prevalence rate of 16.8 (95% CI 16.5–17.2) per 100,000 persons” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“we calculated an adjusted incidence rate of 3.6 per 100,000 persons per year and an adjusted prevalence rate of 18.0 per 100,000 persons to estimate that 58,405 individuals were living with CIDP in the USA in 2019” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, the medical claim codes used in this study may reflect suspected CIDP and may not represent a confirmed clinical diagnosis of CIDP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: Olmsted County, Minnesota, population-based prevalence, 2000
United States: accuracy of CIDP diagnosis codes in claims data
“The PPV of the algorithm requiring at least one CIDP diagnosis code before IVIG use was 66.2% (95% confidence interval [CI], 58.0-74.3). The PPV improved to 71.2% (62.7-79.6) when requiring at least two CIDP codes before IVIG use. The PPV for patients with at least one CIDP code who met the European Academy of Neurology/Peripheral Nerve Society 2021 diagnostic criteria was 30.0% (22.1-37.9).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Global pooled prevalence: systematic review and meta-analysis
“the pooled prevalence rate was 2.81 per 100,000 (95% CI 1.58–4.39; I2 = 99.1%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The crude prevalence rate varied between 0.67 and 7.7 cases per 100,000 persons (Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Substantial heterogeneity in incidence and prevalence across studies seems to be partly explained by using different diagnostic criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Japan: nationwide survey prevalence
“The primary survey showed that the estimated number of patients with CIDP was 4,180, with a prevalence of 3.3 per 100,000 persons.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The male-to-female ratio was 1.5:1, and the median age at onset was 52 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
South Korea: nationwide claims-based prevalence, 2020
United States: patients identified among 6.5 million commercial health plan members, 2011
“CIDP patients from 9 U.S. commercial health plans with claims in 2011 were identified from the Accordant Health Services claims database.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“From 6.5 million covered lives, 73 (56% men; mean age 47) met study entry criteria.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote